Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-400945 for the Treatment of Acute Myeloid Leukemia
NEW YORK and HONG KONG, April 27, 2022 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for unmet needs in cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to CFI-400945, a first in class inhibitor of Polo-like kinase 4 (PLK4), for the treatment of adult patients with relapsed or...
OME Health, a UK-based DIGITAL health company, announces the launch of a novel health and nutrition coaching platform on the heels of a new funding round
LONDON, June 28, 2022 /PRNewswire/ -- OME Health recently closed a new funding round led by Gen-tech Investments, with the participation of global pharmaceutical company Bayer AG, leading athletics company ASICS Ltd., and existing investors. The company also launched a B2B nutrition and health coaching platform to help health professionals manage and scale their practices. OME Health has used...
Seegene to pave way for PCR testing at local clinics with EU-approved multiplex test and fully automated PCR solution
SEOUL, South Korea, June 29, 2022 /PRNewswire/ -- Seegene Inc. (KQ096530), South Korea's leading molecular diagnostics (MDx) company, has obtained EU approval for its Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay that is compatible with the company's fully automated 'AIOS' (All-in-One System). This is expected to help small hospitals, local clinics, and public health centers effectively...
United Imaging To Feature Leaders of Choice Program, Innovative Purchasing Models, and World’s-First Equipment at AHRA in Phoenix
Leaders of Choice is the educational program United Imaging and AHRA Announced Jointly in May. HOUSTON, July 7, 2022 /PRNewswire/ -- United Imaging confirmed that its Houston-based U.S. leadership team will be on hand in Phoenix for the AHRA (Association for Medical Imaging Management) Annual Meeting starting this weekend. The two organizations announced the Leaders of Choice program...
Bushu Pharma Lauded by Frost & Sullivan for Enabling the Launch of Specialty Drugs in Japan and Asia-Pacific and Offering Customer Value with Its Advanced Gateway to Asia Services
The Gateway to Asia initiative ensures quality and timely delivery through shorter lead times, temperature and humidity control, and streamlined urgent order processing SAN ANTONIO, July 27, 2022 /PRNewswire/ -- Based on its recent analysis of the pharmaceutical supply chain contract services industry, Frost & Sullivan recognizes Bushu Pharma with the 2022 Japan...
Pulnovo Medical Limited’s PADN Technology Included in 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of PH
SHANGHAI, Sept. 7, 2022 /PRNewswire/ -- A globally recognized OTM innovative platform Pulnovo Medical Limited's proprietary Pulmonary Artery Denervation (PADN) technology has been included in the 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of pulmonary arterial hypertension (PAH) (hereinafter referred to as "the Guidelines"), jointly issued by the European Society of Cardiology (ESC) and the European Respiratory Society (ERS),...
First patient enrolled in Erectile Dysfunction prospective randomized study with SELUTION SLR
GENEVA, Switzerland, Sept. 10, 2022 /PRNewswire/ -- An 82-year-old Taiwanese man has become the first patient to be enrolled in the initial Erectile Dysfunction (ED) randomized clinical trial (RCT) involving SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon. MedAlliance_Image The PERFECT-SELUTION FIM (PElvic Revascularization For EreCTile dysfuction-SELUTION First-In-Man) study involves...
Turn Biotechnologies launches eTurna™ delivery platform designed specifically to enable nucleic acid therapeutics
The proprietary platform is versatile, equally effective with different cargoes, routes of administration MOUNTAIN VIEW, Calif., Sept. 13, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced it has created a novel platform to safely and effectively deliver nucleic acid therapeutics – a major expansion of the...
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Sept. 14, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in and attend one-on-one...
Hexvix®, A Diagnostic Drug of Asieris, is Now Covered by the 2022 Lecheng Global Specialty Drug Insurance
SHANGHAI, Sept. 15, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced today that Hexvix®, a drug used for bladder cancer diagnosis, has been included in the 2022 edition of the Lecheng Global Specialty Drug Insurance Specialty Drug List....
